The device can be used for up to 24 hours or with a maximum of 96 bottles of contrast media, enhancing the workflow and allowing technologists to focus more on patients during procedures. Credit: Svitlana Hulko / Shutterstock.

Bracco Imaging’s US unit Bracco Diagnostics and German medical device manufacturer ulrich have announced 510(k) clearance from the US Food and Drug Administration (FDA) for the rapid exchange and syringeless injector, Max 3, which is designed for magnetic resonance imaging (MRI) procedures.

Max 3 offers easy-to-manage and intuitive features, including direct injection from original contrast media vials, eliminating the need for syringe refilling.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Additionally, the absence of power cables enables flexible positioning within the MRI room, supporting a magnetic field strength of 50mT.

Its ‘Easy-Click-Cassette flex’ comes with SafeConnect, a dedicated connector for patient tubing that ensures contact protection and guards against retrograde contamination.

It can be used for up to 24 hours or with a maximum of 96 bottles of contrast media, enhancing the workflow and allowing technologists to focus more on patients during procedures.

The Max 3 injector also claims to promote environmentally sustainable practices in radiology and is expected to decrease the amount of plastic waste generated in hospitals and help manage disposal costs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bracco Diagnostics sales and marketing senior vice-president Cosimo De Pinto said: “Today’s clearance marks a critical step in delivering the full suite of Bracco’s robust MRI portfolio.”

Bracco Imaging CEO and vice chairman Fulvio Renoldi Bracco said: “This clearance underscores Bracco’s commitment to pushing the boundaries of innovation in 2024 and beyond while implementing sustainable production in all aspects of our business model.

“At Bracco, we always strive for advancements, and it’s remarkable to see how innovative diagnostic imaging solutions have transformed the MRI industry. Each step gets us closer to redefining the standard of patient care to meet today’s clinical needs.”

In November 2023, Bracco signed a long-term strategic partnership with ulrich medical, aimed at introducing a Bracco-branded, MRI injector to the US market, with a focus on enhancing quality and efficiency for healthcare providers.

In October 2020, Bracco Diagnostics launched the CardioGen-82 infusion system.